Media Articles Related to Guanfacine
Shire receives European approval for INTUNIV as a non-stimulant ADHD treatment for children and adolescents
Source: ADHD / ADD News From Medical News Today [2015.09.21]
Shire has announced that the European Commission granted Marketing Authorisation for once-daily, non-stimulant INTUNIV® (guanfacine hydrochloride prolonged release tablets) for the treatment of...
CHMP Backs Selexipag for Pulmonary Arterial Hypertension
Source: Medscape Family Medicine Headlines [2016.01.29]
Selective prostaglandin receptor agonist has mechanism distinct from prostacyclin and its analogs.
Actelion receives Health Canada approval for Uptravi (selexipag) for the long-term treatment of pulmonary arterial hypertension
Source: Cardiovascular / Cardiology News From Medical News Today [2016.01.26]
Actelion has announced that Health Canada has granted a Notice of Compliance (NOC) approving the orally active, selective IP prostacyclin receptor agonist Uptravi (selexipag),originally discovered...
The age-related change of angiotensin receptor promotes hypertension
Source: Hypertension News From Medical News Today [2016.01.20]
Heterodimerization of AT1R with P2Y6R along with age promotes angiotensin II-induced hypertension.
Formulation scientists to rescue patients with pulmonary arterial hypertension
Source: Huntingtons Disease News From Medical News Today [2016.01.15]
Overview of a type of high blood pressure of the arteries of the lungs and the heart and a new patient-friendly inhalation treatment.
Published Studies Related to Guanfacine
Efficacy of guanfacine extended release assessed during the morning, afternoon,
and evening using a modified Conners' Parent Rating Scale-revised: Short Form. 
attention-deficit/hyperactivity disorder (ADHD)... CONCLUSIONS: These results provide further support for the demonstrated efficacy
Randomized, double-blind trial of guanfacine extended release in children with
attention-deficit/hyperactivity disorder: morning or evening administration. 
CONCLUSIONS: GXR administered either in the morning or evening was associated
Naltrexone with or without guanfacine for preventing relapse to opiate addiction
in St.-Petersburg, Russia. 
induced craving and have reduced opiate relapse in small clinical trials... CONCLUSIONS: Adding guanfacine to naltrexone did not improve treatment retention
Guanfacine extended-release: in attention deficit hyperactivity disorder. [2010.09.10]
Guanfacine, an alpha(2A)-adrenoceptor agonist, is available in the US as an extended-release (ER) tablet for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents (aged 6-17 years). In two large, randomized, double-blind, placebo-controlled trials of 8 and 9 weeks' duration, guanfacine ER (1-4 mg once daily) was effective in reducing the symptoms of ADHD (hyperactivity, impulsivity and inattention) in children and adolescents...
Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. [2010.09.01]
CONCLUSIONS: In this population of children aged 6-12 years with ADHD and the presence of oppositional symptoms, significant reductions in CPRS-R:L oppositional subscale and ADHD-RS-IV total scores were observed with guanfacine XR treatment compared with placebo. Treatment with guanfacine XR at optimized doses was associated with mostly mild or moderate TEAEs. The findings of this study support the efficacy of guanfacine XR in the treatment of children with ADHD and the presence of oppositional symptoms. Clinical Trial Registration Number: NCT00367835.
Clinical Trials Related to Guanfacine
PK/PD Comparison of Guanfacine ER and IR [Active, not recruiting]
Evaluate whether a 4mg/day or 6/mg day dose of extended-release guanfacine produces
pharmacokinetic/dynamic (PK/PD) properties similar to 3mg/day immediate release guanfacine.
Efficacy and Safety Eval of Guanfacine Hydrochloride in Combination With Psychostimulants in Adults (18-65). [Completed]
This is considered an investigator-initiated clinical research trial, which means that your
study doctor is researching a particular medication (in this case a medication that is
currently FDA- approved) for the treatment of AD/HD in individuals ages 6-17. The medication
is guanfacine hydrochloride.
The hypothesis is that this medication could be used in adults with Attention
Deficit/Hyperactivity Disorder who have not received satisfactory results with their current
stimulant ADHD medication. The study drug is investigational for use in adults.
Investigational means it has not been approved by the U. S. Food and Drug Administration
(FDA) for use in adults.
Open-Label Pilot Study of Guanfacine-Extended Release for the Treatment of Cannabis Dependence [Completed]
The purpose of this study is to determine whether guanfacine represents a tolerable,
potentially effective pharmacotherapy option for cannabis dependence. Interested in seeing
whether guanfacine treatment reduces marijuana consumption, withdrawal symptoms, and craving
as compared to baseline.
Does Guanfacine Attenuate Stress-Induced Drinking? [Recruiting]
Evaluating the effect of guanfacine on alcohol consumption. The investigators hypothesize
that guanfacine versus placebo will decrease the number of drinks consumed during the 2-hour
self-administration period across stress and neutral/relaxing conditions.
Effect of Guanfacine on the Reversal of Opioid-induced Hyperalgesia (OIH) [Recruiting]
Combination of guanfacine with opioid medication as a standard treatment for chronic pain.
Reports of Suspected Guanfacine Side Effects
Confusional State (3),
Coordination Abnormal (3),
Swelling Face (3),
Swollen Tongue (3),
Blood Pressure Decreased (3),
Complex Partial Seizures (3),
LIP Swelling (1), more >>